Founders

Oncopeptides’ founders included some of Sweden’s leading oncology, clinical and medical researchers, many with international reputations in their fields.

Combined, Oncopeptides’ founders have published in more than 770 scientific publications, principally in the fields of oncology, cell biology and pharmacology.

Hans Ehrsson
MD, Professor of Analytical Pharmaceutical Chemistry at the Department of Oncology- Pathology, Karolinska Institute.

Prof Ehrsson was professor in analytical pharmaceutical chemistry at Uppsala University from 1984 to 2001. The main focus of Prof Ehrsson’s research is on the bio-analysis, pharmacokinetics and metabolism of alkylating and platinum containing anticancer drugs.

He has published more than 100 scientific publications.

Joachim Gullbo
MD, PhD, MSc Pharm, Associate Professor in Experimental Clinical Pharmacology.

Dr Gullbo has a scientific background in development and evaluation of anti-cancer drugs, from the early stages of lead identification and in vitro assays, to toxicology and proof-of-concept investigations in animal models and clinical trials.

He has co-authored more than 75 scientific publications within the cancer field, and has supervised two PhD students working with alkylating peptides.  

Dr Gullbo has clinical specialist training in Clinical Pharmacology and Oncology and is currently appointed Head of Oncology at Uppsala University Hospital. He is an active scientific consultant of Oncopeptides.

Rolf Larsson
MD, PhD, Professor of Clinical Pharmacology at Uppsala University Hospital and Consultant in Clinical Pharmacology, Uppsala University Hospital.

Prof Larsson has a background in medical cell biology, and is a researcher in Clinical Pharmacology.

He has published more than 250 scientific publications in the field of cancer research.

Prof Larsson has for many years been scientific secretary of the regional ethics committee and is currently facility director of the SciLife drug discovery and development (DDD) platform.

He is also vice chairman of the board for research and development representing the laboratories of Uppsala University hospital.

Rolf Lewensohn
MD, PhD, Professor of Oncology at Karolinska Institutet.

Prof Lewensohn has a position as senior consultant at The Department of Oncology, Karolinska University Hospital and is also Director of Karolinska Clinical Biomics Centre.

Prof Lewensohn has a scientific background in DNA repair and apoptotic signaling in cancer, related to cancer therapy.

He has published 110 scientific publications within the cancer field, and is member of the scientific board of several funding bodies e.g. the Swedish Cancer Society, The Stockholm Cancer Society and King Gustav V’s Jubilee fund.

Kristina Luthman
PhD, Professor of Medicinal Chemistry at Gothenburg University.

The focus of Dr Luthman’s research is in the field of design and synthesis of peptides and peptidomimetics with various biological activities, e.g. cytotoxic activities. Another research interest is the identification of molecular properties of importance for drug transport across biological membranes.

She has published more than 97 scientific publications and has five patent applications.

Peter Nygren
MD, PhD, Professor of Oncology at Uppsala University Hospital and Consultant in Clinical Oncology, Uppsala University Hospital.

Prof Nygren has a scientific background in cell biology and is a researcher in clinical oncology focused on gastrointestinal cancer. The focus of his research is predictive tests for anticancer drugs and new drug development.

He was Medical Head of the clinical trials unit, Department of Oncology, Uppsala University Hospital and was assistant scientific secretary at the Swedish Cancer Society for six years.

He has published approximately 140 scientific publications within the cancer field and had three years regulatory experience assessing new anticancer drugs at the Swedish Medical Products Agency.